Hypotension and bradycardia, a serious adverse effect of piribedil, a case report and literature review
Open Access
- 27 December 2018
- journal article
- case report
- Published by Springer Nature in BMC Neurology
- Vol. 18 (1) , 221
Abstract
Dopamine agonists (DAs) are efficacious for the treatment of motor and nonmotor symptoms in patients with Parkinson’s disease (PD). The treatment of PD with DAs is often complicated by adverse drug reactions (ADRs) of dopaminergic and non-dopaminergic origins. The DA piribedil is widely used in Asian, European, and Latin American countries; therefore, its ADRs are pertinent to clinicians. Here we present a rare case of hypotension and bradycardia that is significantly related to the dosage of piribedil. A middle-aged male, diagnosed with PD, received dopamine replacement with piribedil. When taking 50 mg piribedil daily dose, the patient didn’t feel any discomfort. Two hours after taking 100 mg piribedil he presented with serious concomitant hypotension and bradycardia with a blood pressure (BP) reading of 85/48 mmHg and a heart rate (HR) of 45 beats/min when sitting. After taking 75 mg piribedil, the patient showed the same symptoms with BP reading at 70/45 mmHg and HR of 47 beats/min in the same position. Upon replacing treatment with pramipexole 0.125 mg, 0.25 mg, and 0.375 mg three times a day, no further cardiovascular effects persisted. No studies have previously reported the simultaneous observation of position-unrelated hypotension and bradycardia after taking small doses of piribedil. More studies are needed to explore the effects of DAs on BP and HR, especially piribedil. Piribedil is efficacious for the treatment of PD, but it is important to weigh the potential risk of hypotension and bradycardia against the clinical benefits of this drug.Keywords
Funding Information
- Natural Science Foundation of Guangdong Province (2017B030311015, 2015A030313536)
- Medical Research Fund of Guangdong Province, (A2017317)
- National Key R&D Program of China (2017YFC1310200)
- National Natural Science Foundation of China (81671275, 81501112)
This publication has 30 references indexed in Scilit:
- Epidemiology and etiology of Parkinson’s disease: a review of the evidenceEuropean Journal of Epidemiology, 2011
- Dopamine Receptor Agonists for the Treatment of Early or Advanced Parkinsonʼs DiseaseCNS Drugs, 2010
- Clinical Review and Treatment of Select Adverse Effects of Dopamine Receptor Agonists in Parkinsonʼs DiseaseDrugs & Aging, 2010
- Pharmacokinetic Optimisation in the Treatment of Parkinson???s DiseaseClinical Pharmacokinetics, 2006
- Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in ratsClinical and Experimental Pharmacology and Physiology, 2004
- Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre studyJournal of Neurology, Neurosurgery & Psychiatry, 1999
- Current Status of Dopamine Agonists in Parkinson??s Disease ManagementDrugs, 1993
- Comparative Effects of Dopaminergic Agonists on Cardiovascular, Renal, and Renin-Angiotensin Systems in Hypertensive PatientsThe Journal of Clinical Pharmacology, 1992
- Selective antagonism of the hypotensive effects of dopamine agonists in spontaneously hypertensive rats.Hypertension, 1986
- Peripheral dopamine receptors, potential targets for a new class of antihypertensive agentsLife Sciences, 1982